Advances in the use of Janus kinase inhibitors - PubMed
4 hours ago
- #Janus kinase inhibitors
- #immune-mediated inflammatory diseases
- #rheumatoid arthritis
- Janus kinase inhibitors (JAKi) like tofacitinib, baricitinib, upadacitinib, and filgotinib have been approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and atopic dermatitis.
- Safety concerns have emerged from postmarketing studies, particularly for tofacitinib, showing increased risks of venous thromboembolism and major adverse cardiovascular events in RA patients over 50 with cardiovascular risk factors.
- Ongoing research aims to develop more selective JAKi, such as deucravacitinib, a TYK2 inhibitor, which may offer a better safety profile.
- Clinical trials are exploring JAKi for new indications like lupus, inflammatory myopathies, and Sjogren's syndrome, with some positive results in phase 2/3 trials.
- The review provides updates on JAKi's efficacy, safety data from real-world use, and the development of next-generation inhibitors with improved selectivity.